Premium
High‐dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy
Author(s) -
Brannagan Thomas H.,
Alaedini Armin,
Gladstone Douglas E.
Publication year - 2006
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.20524
Subject(s) - multifocal motor neuropathy , medicine , cyclophosphamide , refractory (planetary science) , mismatch negativity , polyradiculoneuropathy , surgery , gastroenterology , chemotherapy , immunology , physics , electroencephalography , guillain barre syndrome , psychiatry , astrobiology
Patients with multifocal motor neuropathy (MMN) respond to intravenous immune globulin (IVIg) and cyclophosphamide, although the benefit is not sustained. High‐dose cyclophosphamide can induce a remission in patients with autoimmune diseases, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We describe a patient with refractory MMN who improved with high‐dose cyclophosphamide (50 mg/kg for 4 days) without stem cell rescue. Following treatment she discontinued IVIg. At a 6‐month examination, her strength had improved and she had regained the ability to write. High‐dose cyclophosphamide may be a successful treatment for patients with MMN refractory to other therapies. Muscle Nerve, 2006